The neuropathic pain global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Neuropathic Pain Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The neuropathic pain market size has grown strongly in recent years. It will grow from $4.95 billion in 2023 to $5.35 billion in 2024 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to increasing demand for neuropathic pain drugs, chronic pain epidemic, growing demand for prescription treatments, government initiatives.
The neuropathic pain market size is expected to see strong growth in the next few years. It will grow to $7.16 billion in 2028 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to growing awareness of neuropathic pain, aging population, well-proliferated healthcare sector, accessibility to neuropathic pain treatments. Major trends in the forecast period include improved diagnostics, advancements in pain management, advancements in medical research, new drug approvals, strategic initiatives.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/neuropathic-pain-global-market-report
Scope Of Neuropathic Pain Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Neuropathic Pain Market Overview
Market Drivers –
The growing prevalence of chronic pain is expected to propel the growth of the neuropathic pain market going forward. Chronic pain is persistent and ongoing pain that lasts beyond the expected healing time of an injury or illness. It is characterized by its duration, typically lasting at least three to six months or more. The rising prevalence of chronic pain, including neuropathic conditions, requires effective treatments, spurring research, innovation and investment in improved therapies to enhance symptom relief and quality of life. For instance, in April 2023, according to the Morbidity and Mortality Weekly Report (MMWR) published by the Centers for Disease Control and Prevention, a US-based national public health agency, approximately 51.6 million U.S. adults (20.9%) dealt with chronic pain and 17.1 million (6.9%) experienced high-impact chronic pain in 2021. Further, the prevalence of chronic pain among U.S.-born individuals (21.6%) was almost twice that of those born outside the U.S. (11.9%). Similarly, high-impact chronic pain was more prevalent among U.S.-born individuals (7.0%) than those born outside the U.S. (4.1%). Therefore, the growing prevalence of chronic pain is driving the growth of the neuropathic pain market going forward.
Market Trends –
Major companies operating in the neuropathic pain market are adopting artificial intelligence technologies for advanced diagnosis, tailored treatment plans, real-time monitoring, drug discovery and data-driven insights to enhance patient outcomes and refine pain management strategies. For instance, in March 2023, Nevro Corp., a US-based medical device company, launched the Senza HFX iQ spinal cord stimulation (SCS) system. This innovative technology employs artificial intelligence (AI) to customize pain relief for individual patients. The system, which includes the HFX iQ Implantable Pulse Generator (IPG), HFX Trial Stimulator, Charger and HFX App, is designed to treat non-surgical back pain and painful diabetic neuropathy by adapting to patient responses and feedback. It uses a unique algorithm based on extensive patient data and allows patients to adjust their pain relief program via a smartphone app. The system’s digital environment enables data collection and potential updates. The technology aims to enhance pain relief through consistency and personalization, marking a significant advance in SCS therapy.
The neuropathic pain market covered in this report is segmented –
1) By Treatment: Medications; Multimodal Therapy
2) By Diagnosis: Imaging; Blood Tests And Physical Examination
3) By Indication: Diabetic Neuropathy; Spinal Stenosis; Chemotherapy-Induced Peripheral Neuropathy; Other Indications
4) By End User: Hospitals; Clinics; Home Healthcare; Ambulatory Surgical Centers; Other End Users
Get an inside scoop of the neuropathic pain market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=12922&type=smp
Regional Insights –
North America was the largest region in the neuropathic pain market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neuropathic pain market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Key Companies –
Major players in the neuropathic pain market are Pfizer Inc., Johnson & Johnson Private Limited, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline PLC, Medtronic Inc., Eli Lilly and Company, Stryker Corporation, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Boston Scientific Corporation, Biogen Inc., Zimmer Biomet Holdings Inc. , Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Grünenthal GmbH, Lupin Ltd., NuVasive Inc., Integer Holdings Corporation, Avanos Medical Inc., Orthofix Medical Inc., Nevro Corp., InvaGen Pharmaceuticals Inc., B. Braun Melsungen AG, Cirtec Medical Corp., Centaur Pharmaceuticals Pvt Ltd., Stimwave LLC, DePuy Synthes.
Table of Contents
1. Executive Summary
2. Neuropathic Pain Market Report Structure
3. Neuropathic Pain Market Trends And Strategies
4. Neuropathic Pain Market – Macro Economic Scenario
5. Neuropathic Pain Market Size And Growth
…..
27. Neuropathic Pain Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model